Genotype analysis of rotaviruses isolated from children during a phase III clinical trial with the hexavalent rotavirus vaccine in China

• DOI: 10.1016/j.virs.2023.11.002
• Publication Date: 2023-11-14T21:24:50Z
• Authors: Wenqi Zou; Qingchuan Yu; Yan Liu; Qingliang Li; Hong Chen; Jiamei Gao; Chen Shi; Ying Wang; Wei Chen; Xuan Bai; Biao Yang; Jiuwei Zhang; Ben Dong; Bo Ruan; Liuyifan Zhou; Gelin Xu; Zhongyu Hu; Xiaoming Yang
• Keywords: Rotavirus vaccine

The oral hexavalent live human-bovine reassortant rotavirus vaccine (RV6) developed by Wuhan Institute of Biological Products Co., Ltd (WIBP) has finished a randomized, placebo-controlled phase III clinical trial in four provinces China 2021. trail demonstrated that RV6 high efficacy against the prevalent strains and is safe for use infants. During (2019–2021), 200 rotavirus-positive fecal samples from children with RV gastroenteritis (RVGE) were further studied. Using reverse transcription–polymerase chain reaction high-throughput sequencing, VP7 VP4 sequences obtained their genetic characteristics, as well differences antigenic epitopes VP7, analyzed detail. Seven genotypes identified. predominant genotype was G9P [8] (77.0%), followed G8P (8.0%), G3P (3.5%), [9] (1.5%), G1P (1.0%), G2P [4] G4P [6] (1.0%). amino acid sequence identities G1, G2, G3, G4, G8, G9 isolates compared to 98.8%, 98.2%–99.7%, 88.4%–99.4%, 98.2%, 94.2%–100%, 93.9%–100%, respectively. Notably, , exhibited similarity sequence, only minor Chinese endemic strains. This supports potential application preventing diseases caused rotaviruses.